UT 231B

Drug Profile

UT 231B

Alternative Names: UT 231; UT-231B

Latest Information Update: 19 Jun 2007

Price : $50

At a glance

  • Originator Pfizer; University of Oxford
  • Class
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No

Highest Development Phases

  • No development reported Hepatitis C

Most Recent Events

  • 19 Jun 2007 No development reported - Phase-II for Hepatitis C in USA (PO)
  • 31 Jul 2003 Phase-II clinical trials in Hepatitis C in USA (PO)
  • 07 May 2003 Synergy Pharmaceuticals has been acquired by Webtronics
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top